Background Self-directed pedometer use increases physical activity levels in the general population; however, evidence of benefit for Type 2 diabetes is unclear and has not been systematically reviewed for accelerometers.
Introduction
One of the main factors underlying Type 2 diabetes is an imbalance between energy expenditure and intake. Physical activity increases energy expenditure, improving glycaemic control and therefore reducing the risk of diabetes-related complications [1] . Physical activity also exerts an indirect health benefit through influencing weight loss and blood pressure [2] ; however, the majority of people with Type 2 diabetes are either not physically active, or are less active than people without diabetes [3, 4] .
Free-living physical activity, defined as 'non-formal and self-directed physical activity', offers advantages over structured exercise in terms of convenience and acceptability [5] . Evidence suggests that this type of physical activity can reduce mortality and morbidity both in sedentary people [6] [7] [8] and in people with Type 2 diabetes [7, 9, 10] . However increased free-living physical activity is usually achieved through complex and resource-intensive interventions, which are usually not feasible in routine clinical care [11] .
The increasing commercial success of physical activity monitoring devices (pedometers and accelerometers) indicates a public acceptability and enthusiasm for self-monitoring within the general population. Pedometers are tilt devices that simply display step-count. Accelerometers, a more recent technology, use time-based movement sensors, logging the time and intensity of activity and periods of inactivity. 'Steps', being a popular metric for users, are estimated via algorithms, and often displayed on accelerometers. For the purposes of the present study we will consider pedometers as those devices that can only log step-count, and accelerometers as those that can log time and intensity of activity.
Available evidence suggests that the routine use of activity monitors can motivate modest but significant increases in physical activity within the general population [12] and within obesity research [13] , and have beneficial effects on body weight [14] . A number of reviews have also reported a positive impact of activity monitors on people with Type 2 diabetes [15] [16] [17] [18] [19] . The additional information displayed on accelerometers, such as exercise intensity or estimated expended calories, may enhance the effect of some behaviour change techniques (such as goal setting or feedback on performance), increasing motivation and therefore physical activity [20] [21] [22] . No systematic review, however, has specifically examined the effects of accelerometer use alone, or contrasted the impact of pedometers and accelerometers on physical activity behaviour within Type 2 diabetes.
Our primary aim was to review systematically the impact of accelerometer and pedometer-use on free-living physical activity and HbA 1c in people with Type 2 diabetes. Secondary objectives were to investigate the effects on blood pressure, lipid profile and body weight.
Methods
This review was conducted according to a protocol (PROSPERO CRD42015025980) and is reported in line with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [23] .
Data sources and searches
We conducted electronic searches in Medline, EMBASE, Science Citation Index & Conference proceedings Citation Index (ISI Web of Knowledge), Cumulative Index of Nursing and Allied Health (CINAHL), SportDiscus and The Cochrane Central Register of Controlled Trials (CENTRAL) using predefined search strategies (Appendix S1) designed by an experienced information specialist (N.R.). Searches extended from 1945 to August 2016 and included all studies published in English and abstracts translated into English. Manual searching of relevant references using the snowballing technique (starting from the selected studies) was performed by one of the authors (R.B.). Search results were stored and managed using the reference manager software EndNote 7.0.
Study selection
Eligible studies included randomized controlled trials, cluster randomized controlled trials, non-randomized controlled studies and crossover studies. The studies had to evaluate interventions based on the use of accelerometer or pedometer to increase free-living physical activity. Physical activity was considered to be 'free-living' if specifically stated or adequately described in the methods as being non-formal and self-directed [5] . We included studies in adults (age ≥18 years) with Type 2 diabetes. Composite interventions with diet, or other strategies, outside of routine care were included, provided the role of the activity monitor within the intervention was clearly reported and a similar comparator group, without the monitor, was present. Studies of compound devices using both pedometer and accelerometer technology, were included and counted as accelerometers because of the appearance of data displayed to the participant. We excluded interventions based on monitoring technologies in smartphone apps, because they frequently include additional features (e.g. sending reminders, motivational messages, or sharing monitoring data on social media) with potential to induce behaviour change through other mechanisms not strictly related to physical activity monitoring (e.g. provision of general encouragement, instructions, contingent rewards or information about others' approval). For comparator groups, we included usual and enhanced usual-care strategies and behavioural interventions minus the activity monitor, allowing the effect of the monitor to be differentiated.
Titles and abstracts of relevant citations retrieved by the search were screened for eligibility. Full texts were obtained and read for those meeting the selection criteria.
Studies meeting the criteria, according to two independent reviewers (R.B., I.R.C.), were selected for inclusion. Any disagreements were resolved by consensus with a third reviewer (A.F.).
Data extraction and quality assessment
We used structured forms to extract data on study design, intervention duration, sociodemographic characteristics of the participants, sample size, setting, device type and trial outcomes (physical activity, HbA 1c , lipid profile, blood pressure and body weight).
Risk of bias was independently appraised by two reviewers (R.B. and I.R.C.) using the Cochrane Collaboration's tool What's new?
• The increasing popularity of physical activity monitors and the associated motivational effects on the wearer in the general population suggests a possible role within Type 2 diabetes management.
• This systematic review shows that activity monitor use increases free-living physical activity in people with Type 2 diabetes, and suggests that accelerometers have a similar effect to pedometers despite functional differences.
• Together both types of monitor can initiate activity behaviour in sedentary users, on which to build additional interventions. Available trials, however, do not provide evidence that activity monitors alone produce significant improvement in clinical outcomes.
[24]. We quantified reviewer agreement on trial 'risk of bias' using Cohen's j coefficient [25] . Disagreements were solved by consensus with a third reviewer (A.F.). The methodological quality of each article was classified according to six aspects: selection bias; study design; confounders; blinding; data collection; and withdrawals and dropouts.
Data synthesis and analysis
Results were summarized quantitatively and qualitatively. Trials were qualitatively summarized in terms of brief descriptions of the intervention and outcomes. We extracted the mean and SD values of the reported measures for freeliving physical activity, HbA 1c levels [mmol/mol (%)] and blood pressure (mmHg). Data for each outcome were pooled using random-effects models (chosen at protocol stage because of heterogeneity between the different interventions). Overall differences between intervention and control groups were calculated using standardized (SMD) or weighted mean differences, as appropriate, with 95% CIs. Heterogeneity was quantified using the I 2 statistic, where I 2 > 50% was considered evidence of substantial heterogeneity [24] . Heterogeneity, where identified, was explored, through sub-group analysis by: type of monitoring device; duration of diabetes; and intervention duration. Sensitivity analyses were performed to test the effect on outcomes of monitor intervention, alone or nested and full or partial randomization. For each metaanalysis, funnel plots and Egger's test were used to examine potential publication bias. All meta-analyses were conducted using STATA v.12.0. We set a threshold of P = 0.05 to accept statistical significance.
Results
The search process is summarized in the PRISMA flow diagram (Fig. 1) . By screening of title and abstracts, 4352 initial citations were reduced to 146 for further review by full text. After inter-reviewer consensus, 19 studies were excluded and 12 studies were selected for the review [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] .
Features of the trials
The main characteristics of the 12 trials identified are summarized in Table 1 . Individual trial characteristics and outcomes are summarized in Appendix S2. The trials included a total of 1458 participants. Eight trials were set in differing countries, covering three continents. Interventions were delivered in a narrow range of settings; either primary care (four studies) or combined hospital diabetes outpatient clinics and primary care (eight studies). Four trials were conducted in urban settings, one rural and two mixed (not specified in five studies). Ten trials examined the impact of the intervention on physical activity, and nine on HbA 1c . Participants were diverse in terms of age (ranging from 35 to 89 years). The average HbA 1c levels across trials ranged from 48 to 63 mmol/mol (6.5-7.9%). The mean duration of diabetes for each study ranged from 0.5 to 6 years (four studies), to 7 to 11 years (three studies) and was not specified in five studies. Because of similar eligibility criteria, participants from all studies were physically mobile, with no diabetic, renal, cardiovascular or neurological complications. In 10 trials participants had high mean levels of sedentary behaviour and obesity. Three trials excluded people on insulin therapy [27, 35, 36] . One trial specifically targeted recently diagnosed Type 2 diabetes [27] . One trial specifically examined people with Type 2 diabetes and comorbid depression [33] .
Interventions
Interventions were diverse in design and duration. The mean intervention including follow-up time was 8 months, ranging from 5 weeks [26] to 18 months [34] . Nine studies were on pedometers [27] [28] [29] [30] [31] [34] [35] [36] [37] and three were on accelerometers [26, 32, 33] . Five studies [26, 27, 29, 31, 32] comprised activity monitors alone, with minimal additional intervention (usually a motivational manual). In the remaining studies the activity monitor was nested within a complex intervention, where the effect of the behavioural component was minimized by a matched comparator. There was a diverse range of behavioural interventions based on the degree and type of supervision. Studies comprising supervised interventions were group-based [29, 31, 36] , with the remainder being one-to-one; either in-person (seven studies) or telephonebased [33, 34] . Six studies encouraged setting self-derived activity targets, four were set and supervised by staff and two studies set no specific goal [29, 35] . All but one 'routine care' controls were, in practice, enhanced care, usually involving provision of additional clinic visits and educational materials. Control group physical activity measurement methods varied from blinded devices to self-report questionnaires (Appendix S2).
Intervention providers were research staff in seven studies, routine healthcare professionals in four studies and both in one study. Information on the fidelity of intervention delivery was reported in two studies, employing scripted counselling to ensure consistency in one study [36] and staff review meetings and participant rotation in the other [33] .
Risk of bias
Inter-rater agreement was high for assessing risks of bias (k = 0.68). The risks in each domain for individual studies are described in Fig. 2 .
Potential sources of bias were: lack of blinding of participants/staff and of outcome assessment; incomplete outcome data; and underpowered sample sizes. Other sources of bias involved intervention implementation, recruitment methods and eligibility criteria. Nine studies reported numbers of participant withdrawals for each group. The mean study completion rates were 87.8%, where stated, ranging from 97.7% [27] to 60.0% [29] . There were few data on differences in characteristics between completing and non-completing participants. Observed baseline VO 2 fitness and pre-study activity levels were lower in non-completers than completers in two other studies (Plotnikoff et al. [34] and Bjørgaas et al. [28] , respectively). One study noted a male predominance in non-completers [29] . One study observed greater satisfaction levels with pre-study activity levels in the non-completers [33] . In the remaining studies no significant differences were reported between completers and non-completers. Within completers, no study described the differences in characteristics between participants with full and those with partial adherence. Data on intervention adherence was reported in six studies, with adherence levels ranging from 50% to 90%.
Impact of the interventions on free-living physical activity
Data from 10 trials reporting the impact of the interventions on free-living physical activity were pooled in a randomeffects meta-analysis (Fig. 3) . The pooled SMD between intervention (n = 691) and control (n = 681) groups was 0.57 (95% CI 0.24, 0.91) with considerable inter-study heterogeneity (I 2 = 84.0%).
Sub-group analysis by monitor type suggested an absence of significant differences between accelerometers; SMD 0.56 (95% CI 0.27; 0.85) and pedometers; SMD 0.54 (95% CI 0.10; 0.98). Sub-grouping by duration of diabetes, suggested a possible increased effect in diabetes diagnosed within 5 years; SMD 0.82 (95% CI 0.11; 1.54) vs 0.58 (95% CI À0.12; 1.28; Appendix S3). There were no differences between studies grouped by length of intervention of <12 months; SMD 0.51 (95% CI 0.11; 1.13) vs 12 months or more; SMD 0.68 (95% CI 0.30; 1.07; Appendix S4). Egger's test found no evidence of publication bias (P = 0.27; Appendix S5).
Impact of the interventions on HbA 1c
Data from nine trials reporting the impact of the intervention on HbA 1c were pooled in a random effect meta-analysis (Fig. 4) . The pooled weighted mean difference for activity monitor use (n = 552) above control (n = 542), was À0.10 mmol/mol (95% CI À0.13, À0.06). No heterogeneity was identified (I 2 = 0%). Sub-grouping by monitor type did not affect this result. Egger's test found no evidence of publication bias (P = 0.37; Appendix S6).
Impact on the interventions on secondary outcomes
The impact of the intervention on secondary outcomes is reported in Appendix S7a-c. There was no effect on systolic blood pressure across seven studies (n = 534); À0.05 mmHg (95% CI À2.1; 2.0; I 2 = 0%). Similarly, there was no effect on the SMD of pooled weight and BMI data in seven studies (n = 182); +0.10 (95% CI À0.2; 0.3; I 2 = 26%), and of total cholesterol or LDL cholesterol (five studies, n = 142) À0.06 (95% CI À0.3; 0.2; I 2 = 0%). Qualitative data were recorded in five of the studies.
Sensitivity analyses
Testing of the effects of monitor, alone or nested within a complex intervention, on the primary outcome effect estimates did not substantially alter our main results. Effects of quasi-randomization were also non-significant, showing that the assumptions within the inclusion criteria were approximately correct (Appendix S8). All the studies were funded through academic sources.
Discussion
In the present systematic review we identified 12 trials evaluating the impact of interventions based on the use of physical activity monitor devices (pedometers or Diedrich (2010) Plotnikoffi (2013) Paschali (2005) Piette (2011) Tubili (2011) Tudor-Locke (2004) Engel (2006) Furber (2008) Moczulski (2008) Bjorgaas (2008) Andrews ( accelerometers) in people with Type 2 diabetes. We observed that the use of these devices produced a relative increase (SMD) in free-living physical activity of 0.57, or approximately 1 h per week. There were no significant differences between accelerometers and pedometers. No significant effects were observed on HbA 1c , BMI, blood pressure or lipid profile.
Strengths and limitations
The present systematic review used robust methods for study identification, data extraction and analysis, based on data from controlled trials and including a large sample size (n = 1458), with no evidence of significant publication bias. By including recent trials in this field the review provides new evidence supporting the use of monitoring devices to promote free-living physical activity in people with Type 2 diabetes, and was the first to examine accelerometers as distinct from activity monitors overall. This may provide an important first step towards increasing the volume or intensity of physical activity necessary to improve long-term health outcomes.
Our results may be affected by the inherent difficulties of blinding staff or participants in this type of study. In addition the diversity of co-interventions, staff supervision and comparator groups, led to heterogeneity in the pooled estimate of physical activity level (I 2 = 84%), which was partially mitigated by our sub-group analyses. However, there were insufficient numbers of studies of similar cointerventions, such as diaries or counselling, to allow pooling and meta-analysis. Further research is warranted specifically on components of interventions that might boost monitor effectiveness. The inclusion of control groups receiving 'enhanced usual-care' may have resulted in an underestimation of the impact of the interventions for real-world application. However, this served to unify diverse diabetic management types, and also acted as a partial blinding procedure by making both experimental and control groups appear similar to participants. All study participants were physically mobile, without diabetic complications and averaged HbA 1c of 60 mmol/mol (7.6%). Whilst this improved trial combinability, the applicability of the review's results to higher ranges of HbA 1c is reduced.
Comparison with previous reviews Previous reviews have evaluated the effect of activity monitor use in Type 2 diabetes, by examining pedometers alone or by non-specified pooling of both monitor types. Our review confirms the positive findings from two previous reviews with lower numbers of trials and participants, which reported significant increases of 1822 steps per day (equivalent to~115 min/week) [18] and of 2042 steps per day (130 min/week) [19] . The effect size observed in the present review is lower, but still clinically relevant when considering the high levels of sedentary behaviour in people with Type 2 diabetes [20] .
No previous review has directly compared accelerometers with pedometers. The present review indicates no significant difference in physical activity between device types, which is possibly surprising given their functional differences. Nonsignificant increases, observed in shorter-duration Type 2 diabetes and longer-duration trials, warrant future research.
The lack of impact on HbA 1c observed in the present review generally concurs with previous reviews which reported either no effect [17, 18] or a small effect [3 mmol/ mol (0.23%)] [19] in glycaemic control. In terms of other clinical outcomes, the present review generally concurs with previous reviews which found no effect on blood pressure [15] , and a small, not clinically relevant effect, on body weight [16, 19] . Although physical activity is known to improve these clinical outcomes, the effect size from monitor use may be insufficient to stimulate change within the trial duration. This lack of impact could also be partially explained by the fact that our meta-analyses were largely dominated by interventions based on pedometer use.
Whereas pedometers may be successful in promoting walking, they are not intended to promote other more intense forms of physical activity, which are known to be more effective in improving clinical outcomes [21] .
Limitations of available evidence and future research needs
Most of the trials identified in the present review included participants with well-controlled baseline HbA 1c levels and reported mid-trial medication changes. This important limitation of current evidence could partially explain the lack of observed impact on HbA 1c and indicates research needed in people with higher levels of HbA 1c , given that such people, on average, have more sedentary lifestyles and may respond differently to a given level of physical activity [38] . Fewer than half of the trials studied participants for >6 months, despite the interest in whether initial improvements with monitors are sustained in the long term. This may have contributed to the lack of observed impact on clinical outcomes, Post-trial qualitative follow-up and network-type studies would allow data capture of social spreads of monitor buying and long-term behaviour change, particularly with the increasing popularity of consumer devices. Indeed many of the included studies would be difficult to repeat with current levels of monitor prevalence. Future research should examine the extent to which simple interventions based on the use of activity monitors and automatic feedback systems can achieve similar gains to those observed from resource-intensive behavioural programmes. Further studies are also needed to identify potential co-interventions that may be added to monitor use to synergize impact.
Nested qualitative studies may prove a valuable resource to better understand the psychological factors potentially leading to the observed increased behaviour change in monitor-based interventions and the influence on other aspects of diabetes self-management, such as diet and medication adherence.
Evidence on the modulating effects of age, gender and ethnicity on engagement and effect size is currently required.
Many of the reviewed activity monitors had limitations, notably that pedometers and accelerometers are unable to detect other non-walking forms of free-living physical activity, such as gardening, swimming or cycling. Recent advances in data processing and integration with smartphones, indicates a need for research into newer devices, in particular new functions and their interaction with people with Type 2 diabetes.
Conclusions
In the present systematic review we observed that, in Type 2 diabetes, the use of accelerometers or pedometers increases free-living physical activity by approximately 1 h per week, but exerts no effect on HbA 1c or other clinical outcomes.
